Unicycive Therapeutics, INC Form 4 insider transactions

Sara Kenkare-Mitra, a Director of Unicycive Therapeutics, Inc., received 47,941 shares of common stock on May 14, 2026.

Sandeep Laumas, a Director of Unicycive Therapeutics, Inc., received 47,941 shares of common stock on May 14, 2026.

Unicycive Therapeutics CEO Shalabh Gupta was granted 762,200 restricted stock units as part of a compensation package.

Director Sara Kenkare-Mitra was granted 126,300 restricted stock units in Unicycive Therapeutics, Inc.

Director Sandeep Laumas was granted 126,300 restricted stock units in Unicycive Therapeutics, Inc. as part of an equity compensation package.

Pramod Gupta, EVP of Pharmaceuticals and BD at Unicycive Therapeutics, was granted 169,500 restricted stock units.

Unicycive Therapeutics CFO John Townsend was granted 169,500 restricted stock units as part of a compensation package.

EVP of Corporate Strategy Douglas Jermasek received a grant of 169,500 restricted stock units from Unicycive Therapeutics.

Unicycive Therapeutics CEO Shalabh K. Gupta was granted 762,200 restricted stock units, vesting over three years.

Director Sandeep Laumas was granted 126,300 restricted stock units in Unicycive Therapeutics, Inc.

Unicycive Therapeutics Director Gaurav Aggarwal converted 3,199.21 shares of Series A-2 Prime Preferred Stock into 652,900 shares of common stock.

Unicycive Therapeutics, Inc. Director Gaurav Aggarwal acquired 21,200 stock options with an exercise price of $4.71, increasing his total beneficial ownership of derivative securities to 39,200.

Unicycive Therapeutics Director Sandeep Laumas was granted 21,200 stock options with an exercise price of $4.71, increasing his total beneficial ownership of derivative securities to 41,286.

Unicycive Therapeutics, Inc. Director Sara Kenkare-Mitra was granted 21,200 stock options with an exercise price of $4.71, increasing her total beneficial ownership of derivative securities to 39,200.

Unicycive Therapeutics, Inc. CEO Shalabh K. Gupta was granted 325,000 stock options with an exercise price of $4.71, aligning executive incentives with long-term shareholder value.

Unicycive Therapeutics, Inc. Chief Financial Officer John Townsend was granted 10,000 stock options with an exercise price of $4.71, vesting over time.

Pramod Gupta, EVP of Pharmaceuticals and BD at Unicycive Therapeutics, was granted 90,000 stock options with an exercise price of $4.71.

Douglas Jermasek, EVP of Corporate Strategy at Unicycive Therapeutics, Inc., was granted 10,000 stock options with an exercise price of $4.71.

Director Gaurav Aggarwal reports a transaction involving the conversion of Series A-2 Prime Preferred Stock into common stock and adjustments to beneficial ownership.

Director Gaurav Aggarwal reports transactions involving Unicycive Therapeutics common stock and Series A-2 Prime Preferred Stock.

John Townsend, CFO of Unicycive Therapeutics, reports the acquisition of stock options.

Douglas Jermasek, EVP of Corporate Strategy at Unicycive Therapeutics, reports acquisition of stock options.

Pramod Gupta, EVP of Pharmaceuticals and BD at Unicycive Therapeutics, reports the acquisition of stock options and updates to beneficial ownership.

Shalabh K. Gupta, CEO of Unicycive Therapeutics, reports acquisition of stock options.

John Townsend, CFO of Unicycive Therapeutics, reports the acquisition of stock options.

Douglas Jermasek, EVP of Corporate Strategy at Unicycive Therapeutics, reports acquisition of stock options.

Pramod Gupta, EVP at Unicycive Therapeutics, reports acquisition of stock options.

Shalabh K. Gupta, CEO of Unicycive Therapeutics, reports acquisition of stock options.